Extending the availability of its endovascular innovations into another major world market, Medtronic, Inc has announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare for the Talent thoracic stent graft, a lifesaving technology that allows more patients to benefit from a minimally-invasive treatment for certain types of aneurysms of the descending thoracic aorta.
At the same time, the Ministry granted approval for the Reliant stent graft balloon catheter, which is used in abdominal and thoracic endovascular procedures to facilitate endograft modeling and fixation to the vessel wall.
Medtronic plans to launch the Talent thoracic stent graft and the Reliant stent graft balloon catheter in Japan after reimbursement approval.
“We look forward to collaborating with physicians in Japan so more patients with aortic aneurysms can avoid open surgical repair, and benefit from our innovative stent graft systems,” said Tony Semedo, vice president of the CardioVascular business and general manager of the Endovascular Innovations division at Medtronic.
“Japan is a high-priority market for Medtronic. Pending the requisite regulatory and reimbursement approvals, in the years ahead, we intend to follow the Talent thoracic stent graft with many other aortic repair technologies from our extensive portfolio and pipeline to extend the option of minimally?invasive treatment to even more patients.”